(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.
The clinical stage drug development company developing sulforaphane-based medicines said the positive update was observed at the laboratories of professors Grace Chen and Duxin Sun, and associate professor Justin Colacino, at the University of Michigan in the US.
Evgen Pharma said the in vitro and in vivo studies, funded by the USA National Cancer Institute and the University of Michigan, will be generating data continuously throughout the project.
"We have shown preliminary signs of anti-tumour activity of SFX-01 in organoids derived from human tumours," said Chen, who was one of the lead investigators.
Evgen Pharma Chief Executive Officer Huw Jones commented: "These early data from our collaborators in the USA show encouraging evidence of activity of SFX-01 in another significant cancer.
"Colorectal or bowel cancer is the third most common cancer worldwide accounting for around one in ten of all cancer diagnoses and a cause of significant morbidity and mortality. We look forward to continuing to work with Professor Chen and colleagues to learn more about SFX-01 in this setting."
Shares in Evgen Pharma were up 3.0% at 1.08 pence each in London on Tuesday morning.
By Greg Rosenvinge, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Evgen Pharma (EVG)